Evidence of graft-versus-tumour effect following allogeneic haematopoietic stem cell transplantation in renal cancer other than clear cell type [2]

Bone Marrow Transplantation

Volumn 34, Issue 10, 2004, Pages 917-918

  Secondino, S ^a   Pedrazzoli, P ^a   Giannetta, L ^a   Schiavetto, I ^a   Vanzulli, A ^a   Siena, S ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FLUOROURACIL; INTERLEUKIN 2; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER CLASSIFICATION; CANCER REGRESSION; CASE REPORT; CELL TYPE; CHIMERA; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED MEDICINE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; KIDNEY CARCINOMA; LETTER; LIVING DONOR; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MYCOSIS; NEPHRECTOMY; PAPILLARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIBLING; T LYMPHOCYTE; VIRUS INFECTION;

ADENOCARCINOMA, PAPILLARY; FATAL OUTCOME; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY NEOPLASMS; LIVER FAILURE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 9444258140     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704669     Document Type: Letter

References (9)

1. Renga M, Pedrazzoli P, Siena S. Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Ann Oncol 2003; 14: 1177-1184.
2. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogenic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
3. Rini BI, Zimmerman T, Stadler WM et al. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024.
4. Van Den Eynde BJ, Gaugler B, Probst-Kepper M et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumour results from reverse strand transcription. J Exp Med 1999; 190: 1793-1800.
5. Dumas F, Gala JL, Berteau P et al. Molecular expression of PSMA mRNA and protein in primary renal tumours. Int J Cancer 1999; 80: 799-803.
6. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85-90.
7. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa 2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1988; 338: 1272-1278.
8. Ueno NT, Cheng YC, Rondo'n G et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumours. Blood 2003; 102 3829-3836.
9. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.